GSK Consumer Healthcare is set to accelerate its growth in China

Wang Yanlin Zhou Shengjie
The year of 2018 has proven to be yet another fertile period for GlaxoSmithKline, one of the world's leading healthcare companies.
Wang Yanlin Zhou Shengjie
Shot by Zhou Shengjie. Edited by Zhou Shengjie.

The year of 2018 has proven to be yet another fertile period for GlaxoSmithKline, one of the world’s leading healthcare companies. With an ambition to help people do more, feel better and live longer, GSK saw its revenue shot to 30.8 billion pounds (US$41 billion) last year. 

The company also took big steps to significantly strengthen its consumer healthcare business sector by announcing the agreement with Pfizer Inc to combine their consumer health businesses into a new world-leading joint venture.

Filippo Lanzi, regional head of Asia Pacific, GSK Consumer Healthcare, talked about the company’s regional strategy for consumer healthcare, which has played a vital role in driving the group’s sustainable growth. 

And for China, Lanzi showed strong confidence and defined the market as the top priority for GSK Consumer Healthcare.


Special Reports

Top